A Phase 4 interventional study of Coenzyme Q10 (drug) in Chronic Renal Failure and Hemodialysis, sponsored by University of Shizuoka. Completed at 1 site in Japan. Open to participants aged 0 Years to 85 Years. Per ClinicalTrials.gov, last updated 2006-03-28.
Sponsored by University of Shizuoka · Phase 4, Interventional, and Treatment
The purpose of this study is to examine whether CoQ10 administration is effective as an antioxidant in hemodialysis patients.
Oxidative stress has been recognized as a potential risk factor for such complications as atherosclerosis in hemodialysis patients. This study investigates whether CoQ10 administration is effective for protecting oxidative stress in hemodialysis patients. The subjects were recruited from day-time hemodialysis patients in Iwata City Hospital. 100 mg CoQ10 was administered every HD for 6 months. Several oxidative and antioxidative markers were measured in plasma at pre, 1, 3, 6 months and after washout.
2,085 studies on the registry are indexed under Kidney Failure, Chronic; 260 are open to participants now.
This study's enrollment of 40 is below the median of 55 across 1,557 interventional studies indexed under Kidney Failure, Chronic.
Browse Kidney Failure, Chronic studies →University of Shizuoka is the lead sponsor of 11 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Oxidative protein concentration at 6 month
Antioxidant capacity at 6 month
This study is completed, as verified in Mar 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Shizuoka